PET-Diagnostics: The main objective of the Project was to develop a PET-product used in Positron emission tomography-computer tomography (PET-CT) for cancer, Alzheimer or Parkinson diagnostics. This Product was created as a result of very tight cross-border cooperation between Estonian and Latvian companies TBD-Biodiscovery and PharmIdea. The outcome of the Project was final dosage form of the PET-product with all the documentation package, necessary for its implementation in nuclear medicine centers and hospitals. After the first Product has been developed and marketed, TBD and PharmIdea plan to continue the cooperation and develop the next PET-products for oncology studies, studies of Alzheimer and Parkinson disease and seek the marketing channels to reach the hospitals worldwide.
Project lead partner: TBD Pharmatech Ltd (formerly TBD-Biodiscovery Ltd)
Partners: PharmIdea Ltd
-------
These short, fun, and informative clips bring to life the successful cooperation between entrepreneurs, researchers and enthusiasts from Estonia and Latvia, who have worked together on joint product or service development. The projects were co-financed by the Estonia-Latvia programme during the 2014-2020 funding period.
For further information visit the Estonia-Latvia programme website: www.estlat.eu
#estlat #interreg #crossbordercooperation #madeinestlat #estlatresults
